Lamal (Lamotrigine)

Lamotrigine blocks voltage‑gated sodium channels on neurons, stabilising the neuronal membrane and reducing the release of excitatory neurotransmitters such as glutamate. This action diminishes abnormal neuronal firing that underlies seizures and mood instability.

The appropriate dose of Lamal is individualised by the prescribing clinician based on the patient’s age, indication, renal or hepatic function, and any concomitant medicines. No fixed regimen is provided here.

Data on lamotrigine use in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the possible risk, and treatment decisions should be made in consultation with a healthcare professional.

Enquiries for Lamal can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lamotrigine and carbamazepine are sodium‑channel blockers used for epilepsy, but lamotrigine has a broader indication that includes bipolar disorder maintenance and is generally associated with a lower risk of certain drug‑enzyme interactions. Carbamazepine may cause more sedation and has a higher potential for inducing hepatic enzymes.

Lamal should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Lamal is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and whether it should be taken with meals depend on the individual treatment plan.

The most serious adverse reactions include severe skin rashes such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and rare cases of aseptic meningitis. Immediate medical attention is required if any of these occur.

Lamal is contraindicated in patients with a known hypersensitivity to lamotrigine or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients who have previously experienced life‑threatening skin reactions to lamotrigine.